Ultragenyx (RARE) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 15 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $35.00 from $32.00 | Sep 21, 2026 |
| Evercore ISI Group | Maintained | In-Line | $18.00 from $16.00 | Sep 21, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $39.00 from $33.00 | Sep 18, 2026 |
| Canaccord Genuity | Maintained | Buy | $39.00 from $37.00 | Sep 18, 2026 |
| Citigroup | Maintained | Buy | $32.00 from $31.00 | Sep 18, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $20.00 from $18.00 | Sep 18, 2026 |
| Citigroup | Maintained | Buy | $31.00 from $28.00 | Sep 17, 2026 |
| Barclays | Maintained | Overweight | $32.00 from $43.00 | Sep 4, 2026 |
| Goldman Sachs | Maintained | Neutral | $19.00 from $28.00 | Sep 4, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $33.00 from $103.00 | Sep 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $50.00 | Sep 3, 2026 |
| Baird | Downgraded | Outperform → Neutral | $16.00 from $40.00 | Sep 3, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $16.00 from $34.00 | Sep 3, 2026 |
| Canaccord Genuity | Maintained | Buy | $37.00 from $83.00 | Sep 3, 2026 |
| Wedbush | Maintained | Neutral | $23.00 from $30.00 | Sep 3, 2026 |
| Wells Fargo | Maintained | Overweight | $18.00 from $50.00 | Sep 3, 2026 |
| Citigroup | Maintained | Buy | $28.00 from $58.00 | Sep 3, 2026 |
| TD Cowen | Maintained | Buy | $18.00 from $49.00 | Sep 3, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Sep 3, 2026 |
| Jefferies | Maintained | Buy | $28.00 from $77.00 | Sep 3, 2026 |
Frequently asked questions
What is the price target for RARE stock?
The average 12-month analyst price target for Ultragenyx (RARE) is $26.73, with a high estimate of $39.00 and a low of $16.00, across 15 analysts.
Is RARE a buy, sell, or hold?
Analysts covering Ultragenyx currently average a Buy rating: 11 buy, 10 hold and 0 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RARE?
The average price target of $26.73 implies 79.42% upside from the last price of $14.90.
What is the latest analyst rating on RARE?
On Sep 21, 2026, Barclays maintained Ultragenyx at Overweight with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.